Influenza Vaccine in Children With Asthma

Overview

The occurence of influenza can be a factor of imbalance of asthma. Asthma patients are recommended for annual influenza vaccination . However there is insufficient vaccination coverage of asthmatic patients despite this recommendation. The aim of this study is to evaluate the rate of influenza vaccination coverage of children with asthma aged from 6 month to 17 years of age followed in pediatric pneumology consultation at the university hospital of Nancy.

Full Title of Study: “Evaluation of the Immunization Coverage Against Influenza in Children With Asthma Followed at the Hospital of Nancy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 2019

Detailed Description

Using a questionnaire, the investigator will estimate the percentage of the asthmatic patients vaccinated against influenza. He will then compare the 2 groups of vaccinated and unvaccinated patients : comparison of patients characteristics, comparison of asthma characteristics (severity, asthma control…). He will also analyze the causes of vaccination or non-vaccination.

Arms, Groups and Cohorts

  • Asthmatic children vaccinated
  • Asthmatic children unvaccinated

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of asthmatic patients vaccinated against influenza
    • Time Frame: through study completion, an average of 6 months
    • Percentage of patients vaccinated against influenza will be evaluate among children with asthma followed in pediatric pneumology consultation.

Secondary Measures

  • Socio-demographic characteristics of patients
    • Time Frame: through study completion, an average of 6 months
    • Socio-demographic characteristics will be recorded from the questionnaire and compare between the 2 groups : vaccinated and unvaccinated patients.
  • Age of patients (years)
    • Time Frame: through study completion, an average of 6 months
    • Age of patients will be recorded from the questionnaire and compared between the 2 groups : vaccinated and unvaccinated patients.
  • Asthma severity (mild, moderate, severe asthma)
    • Time Frame: through study completion, an average of 6 months
    • Asthma severity (mild, moderate, severe asthma) is assessed from the level of treatment required to control symptoms according to Global Initiative for Asthma (GINA) 2018 recommendations. The investigator will compare asthma severity between the 2 groups : vaccinated and unvaccinated patients.
  • Asthma symptom control (well controled, partly controlled, uncontrolled)
    • Time Frame: through study completion, an average of 6 months
    • Level of asthma symptoms control (well controled, partly controlled, uncontrolled) is assessed from symptoms control tool, according to GINA 2018 recommendations. The investigator will compare asthma symptom control between the 2 groups : vaccinated and unvaccinated patients.

Participating in This Clinical Trial

Inclusion Criteria

  • asthmatic patients followed in pediatric pneumology consultation at university hospital of Nancy aged from 6 months to 17 years

Exclusion Criteria

  • asthmatic children who have been followed for less than 1 year

Gender Eligibility: All

Minimum Age: 6 Months

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Central Hospital, Nancy, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Aurore Blondé, Dr, Principal Investigator, CHRU nancy
  • Overall Contact(s)
    • Aurore Blondé, Dr, 0383154603, a.blonde@chru-nancy.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.